Usefulness of F-18-alpha-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer

作者：Kaira Kyoichi; Higuchi Tetsuya; Sunaga Noriaki; Arisaka Yukiko; Hisada Takeshi; Tominaga Hideyuki; Oriuchi Noboru; Asao Takayuki; Tsushima Yoshihito; Yamada Masanobu

来源：Anticancer Research, 2016, 36(12): 6481-6490.

DOI：10.21873/anticanres.11247

• F-18-FAMT
• PET
• therapeutic monitoring
• lung cancer
• metabolic response

Background/Aim: L-[3-F-18]-alpha-methyl tyrosine (F-18-FAMT) positron emission tomography (PET) has a high specificity for detecting malignant lesions. However, the usefulness of therapeutic monitoring of F-18-FAMT PET against advanced human neoplasms remains unclear. Here, we evaluated F-18-FAMT PET clinical significance regarding therapy response and outcome after systemic chemotherapy in patients with advanced lung cancer, compared to F-18-FDG PET. Patients and Methods: All patients with untreated advanced lung cancer received F-18-FAMT PET and F-18-FDG PET before and 4 weeks after one cycle of chemotherapy. Metabolic response (MR) was defined according to the PERCIST guideline. Results: Ninety-five patients were eligible for analysis on both PET scans. The histological type included 87 non-small cell lung cancers and 8 small-cell lung cancers. Post-treatment maximal standardized uptake values (SUVmax) and MR on F-18-FAMT PET were correlated with tumor response. In all patients, post-treatment SUVmax of F-18-FDG and F-18-FAMT PET and MR of F-18-FAMT PET were statistically significant prognostic markers for predicting poor outcome by univariate analysis. Multivariate analysis confirmed that MR on F-18-FAMT PET was a significant independent prognostic factor. Conclusion: MR on F-18-FAMT PET may be a potential parameter to predict the prognosis after first-line chemotherapy in patients with advanced lung cancer.

• 出版日期2016-12